AqVida

Executive Summary

AqVida GmbH is a German pharmaceutical company focused on the development and manufacture of generic oncology drugs, particularly cytostatic injectable solutions. Founded in 2005 (operational from 2008) and headquartered in Greifswald, the company operates a high-tech production facility in Dassow, Germany, which complies with EU GMP and US FDA standards. AqVida emphasizes product safety and supply chain reliability, and also offers GMP consulting and mobile cleanroom container solutions. By specializing in complex generic injectables, the company addresses a growing demand for affordable oncology treatments in Europe and beyond. With its established manufacturing capabilities and adherence to stringent regulatory standards, AqVida is well-positioned to expand its market share in the generic oncology segment. The company's diversified revenue streams, including consulting and cleanroom solutions, provide additional growth avenues. However, as a private entity, financial details are limited. The company's focus on high-demand therapeutic areas and its certified production capacity suggest a steady growth trajectory, though competition remains intense. Overall, AqVida represents a niche but essential player in the global oncology generics market.

Upcoming Catalysts (preview)

• Q4 2026EU Regulatory Approval for New Cytostatic Product70% success
• Q2 2026Expansion of Mobile Cleanroom Container Sales60% success
• Q3 2026Partnership with Major Oncology Distributor50% success